Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C

Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C

Summary Chronic infection with the hepatitis C virus induces liver fibrosis, but it is unknown why some patients progress to advanced fibrosis while others remain with mild disease. Recently, an inverse association between serum levels of dehydroepiandrosterone sulphate (DHEA‐S) and liver fibrosis i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of viral hepatitis Vol. 25; no. 3; pp. 254 - 261
Main Authors: Araujo Neto, J. M., Coelho, H. S. M., Chindamo, M. C., Rezende, G. F. M., Nunes Pannain, V. L., Bottino, A. M. C. F., Bruzzi Porto, L. F., Luiz, R. R., Villela‐Nogueira, C. A., Perez, R. M.
Format: Journal Article
Language:English
Published: England Wiley Subscription Services, Inc 01-03-2018
Subjects:
Biopsy
Chronic infection
Dehydroepiandrosterone
Dehydroepiandrosterone sulfate
dehydroepiandrosterone sulphate
Diabetes mellitus
Fatty liver
fibrogenesis
Fibrosis
Hepatitis
Hepatitis C
Liver
Liver diseases
liver fibrosis
Regression analysis
Serum levels
Steatosis
Sulfate
S‐DHEA
dehydroepiandrosterone sulphate
liver fibrosis
fibrogenesis
S-DHEA
hepatitis C
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Chronic infection with the hepatitis C virus induces liver fibrosis, but it is unknown why some patients progress to advanced fibrosis while others remain with mild disease. Recently, an inverse association between serum levels of dehydroepiandrosterone sulphate (DHEA‐S) and liver fibrosis in patients with nonalcoholic fatty liver disease was described, and it was postulated that dehydroepiandrosterone (DHEA) has antifibrotic effects. Our aim was to compare serum DHEA‐S levels with liver fibrosis in hepatitis C patients. We collected serum samples from hepatitis C patients at the same day they underwent a liver biopsy. S‐DHEA was compared to different stages of fibrosis. Binary logistic regression models were applied to evaluate independent variables associated to fibrosis. We included 287 patients (43.9% male). According to fibrosis stages 0, 1, 2, 3 and 4, median serum DHEA‐S levels were 103 (26‐462), 73 (5‐391), 46 (4‐425), 35 (6‐292) and 28 (2‐115) μg/dL, respectively (P < .001). Median serum DHEA‐S levels were 74 (5‐462) vs 36 (2‐425) μg/dL for mild (F0‐1) vs significant (F2‐4) fibrosis, respectively (P < .001). Median serum DHEA‐S levels were 64 (4‐462) vs 31 (2‐292) μg/dL for non advanced (F0‐2) vs advanced fibrosis (F3‐4), respectively (P < .001). The same association was found when the subgroup of HCV patients with and without steatosis or steatohepatitis was analysed. The association between lower DHEA‐S levels and advanced fibrosis was independent of age, gender, diabetes mellitus, obesity and steatosis. Lower circulating DHEA‐S levels are associated with more advanced stages of liver fibrosis in hepatitis C patients.
Bibliography:Funding information
This work was supported by funding from Post‐Graduation Department of Federal University of Rio de Janeiro and Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Rio de Janeiro, Brazil
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1352-0504
1365-2893
DOI:10.1111/jvh.12812